Unmet Needs in the Management of Patients with Hyperlipidemia

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP

Key Takeaways

Maximally tolerated statin therapy often fails to achieve LDL-C levels below 70 mg/dL in high-risk ASCVD patients, with even greater challenges for levels below 55 mg/dL.
Suboptimal patient adherence to statins necessitates strategies like education, regimen simplification, and side effect management to enhance compliance.
Therapy adjustments, including alternative lipid-lowering agents or combination therapies, are considered when adherence is compromised or LDL-C targets remain unmet.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, discusses how maximally tolerated statin therapy often fails to achieve target low-density lipoprotein cholesterol levels in high-risk patients with atherosclerotic cardiovascular disease and share strategies for optimizing adherence, including when to switch therapies to improve patient outcomes.

Now Viewing

EP: 1.Unmet Needs in the Management of Patients with Hyperlipidemia

Video content above is prompted by the following:

In your clinical experience, how frequently does maximally tolerated statin therapy fail to lower low-density lipoprotein cholesterol levels below 70 mg/dL in high-risk patients with atherosclerotic cardiovascular disease?
How about levels below 55 mg/dL?
Patient adherence to statins is often suboptimal. What are your best methods to optimize adherence?
In which scenarios do you switch patients’ therapies to optimize adherence?